“We are extremely disappointed with the FDA’s decision. We continue to feel strongly that Waylivra demonstrates a favorable benefit/risk profile in people with FCS,” said Akcea CEO, Paula Soteropoulos.
Patients with familial chylomicronemia syndrome who were actively connected were also 3 times as likely to report “high” or “extremely high” motivation in managing their own health.
Antisense technology refers to the use of synthetic nucleic acid sequences to interrupt specific protein production by targeting the corresponding messenger RNA that encodes that protein.
